What is eMolecules?
eMolecules is dedicated to advancing human health by empowering scientists to accelerate therapeutic research. The company provides critical business intelligence data and integrated e-commerce software solutions for managing screening compound, chemical building block, and primary antibody supply chains. These advanced tools, augmented by their acquisition, aggregation, and analytical services, are instrumental for drug discovery researchers across the pharmaceutical, biotechnology, academic, CRO, and agrochemical sectors. Established in 2005 and headquartered in San Diego, eMolecules also maintains offices in Boston and London, employing a team of over 50 professionals.
How much funding has eMolecules raised?
eMolecules has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in eMolecules
PPP
Public-Private Partnership
What's next for eMolecules?
The company's large-scale, late-stage funding context suggests a phase of significant scaling and market expansion. This strategic investment is likely to fuel further development of its data and software platforms, potentially enabling eMolecules to broaden its service offerings and deepen its penetration within the global drug discovery market. Future growth may involve strategic partnerships or acquisitions to enhance its competitive edge in providing essential intelligence and e-commerce solutions to the life sciences industry.
See full eMolecules company page
